A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
Latest Information Update: 14 Mar 2025
At a glance
- Drugs SerpinPC (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms PRESent-2
- Sponsors ApcinteX
- 11 Mar 2025 Status changed from active, no longer recruiting to discontinued.
- 05 Feb 2025 Planned End Date changed from 5 Jun 2026 to 28 Feb 2025.
- 05 Feb 2025 Status changed from recruiting to active, no longer recruiting.